雷公藤多苷片治疗临床蛋白尿期糖尿病肾病的疗效观察

目的:观察雷公藤多苷片治疗临床蛋白尿期糖尿病肾病的有效性与安全性。方法:将92例临床蛋白尿期糖尿病住院患者随机分为试验组和对照组,对照组给予常规降血糖药物治疗,试验组在常规治疗的基础上给予雷公藤多苷片。用药10周后,比较两组患者治疗前后临床症状、尿蛋白(UAlb)、血清白蛋白、血尿素氮(BUN)、血肌酐(Scr)以及体液免疫指标的变化情况。结果:口服雷公藤多苷片治疗的患者临床症状有显著的改善(P<0.05);尿蛋白减少的作用较对照组更为明显,且差异具有统计学意义(P<0.01),但两组患者在治疗前后的BUN和Scr水平无明显改变(P>0.05);血清白蛋白、IgG、IgA、C3、C4水平明显变化;试验组和对照组在治疗期间均未见明显不良反应。结论:雷公藤多苷片可有效改善临床蛋白尿期糖尿病肾病的临床症状,并且大大降低患者的尿蛋白,增强体内免疫抗体,从根本上改善患者的病情,疗效显著,且安全可靠,值得向临床推荐。

Efficacy of Tripterygium Glycosides on Proteinuria Patients with Diabetic Nephropathy

Objective: To observe the efficacy and safety of tripterygium in the treatment of diabetic nephropathy.Methods: Ninety-two diabetic patients with clinical proteinuria were randomly divided into tripterygium group and control group.Patients in control group only received conventional treatment while patients in tripterygium group were given tripterygium on the basis of conventional treatment.After 10 weeks,clinical symptoms,urine albumin,serum indicators such as albumin,BUN,Scr,IgG,IgA,C3,and C4 were compared between the two groups before and after treatment.Results: The clinical symptoms,urine albumin,and immune indicators had significantly changes(P<0.05) in tripterygium groups.Conclusion: Tripterygium glycosides tablet is good in efficacy and safety in the treatment of diabetic nephropathy.